B
321.36
11.67 (3.77%)
| Previous Close | 309.69 |
| Open | 313.00 |
| Volume | 448,937 |
| Avg. Volume (3M) | 375,508 |
| Market Cap | 38,826,393,600 |
| Price / Earnings (Forward) | 126.58 |
| Price / Sales | 7.68 |
| Price / Book | 10.12 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | BeOne Medicines Ltd. | Bullish | - |
AIStockmoo Score
0.0
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2025 | 8,799,053 |
| Hhlr Advisors, Ltd. | 30 Jun 2025 | 1,034,306 |
| Siren, L.L.C. | 30 Jun 2025 | 509,990 |
| Boxer Capital, Llc | 30 Sep 2024 | 500,000 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2025 | 347,787 |
| Capital International, Inc./Ca/ | 30 Jun 2025 | 345,559 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 365.00 (Guggenheim, 13.58%) | Buy |
| Median | 354.50 (10.31%) | |
| Low | 330.00 (Morgan Stanley, 2.69%) | Buy |
| Average | 351.00 (9.22%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 282.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 07 Aug 2025 | 365.00 (13.58%) | Buy | 298.29 |
| RBC Capital | 07 Aug 2025 | 364.00 (13.27%) | Buy | 298.29 |
| 16 Jul 2025 | 349.00 (8.60%) | Buy | 279.16 | |
| JP Morgan | 17 Jul 2025 | 345.00 (7.36%) | Buy | 290.35 |
| 27 Jun 2025 | 321.00 (-0.11%) | Buy | 241.20 | |
| Morgan Stanley | 27 Jun 2025 | 330.00 (2.69%) | Buy | 241.20 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 307.51 | -11,013 | -3,386,608 |
| WU XIAOBIN | - | 308.60 | -89,794 | -27,699,613 |
| Aggregate Net Quantity | -100,807 | |||
| Aggregate Net Value ($) | -31,086,221 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 308.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WU XIAOBIN | Officer | 14 Aug 2025 | Automatic sell (-) | 39,936 | 309.69 | 12,367,780 |
| WU XIAOBIN | Officer | 14 Aug 2025 | Option execute | 39,936 | - | - |
| LEE CHAN HENRY | Officer | 13 Aug 2025 | Automatic sell (-) | 11,013 | 307.51 | 3,386,608 |
| LEE CHAN HENRY | Officer | 13 Aug 2025 | Option execute | 8,230 | - | - |
| WU XIAOBIN | Officer | 13 Aug 2025 | Automatic sell (-) | 49,858 | 307.51 | 15,331,834 |
| WU XIAOBIN | Officer | 13 Aug 2025 | Option execute | 49,858 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |